Orexo AB
€1.35
0
+€0+0% Friday 06:10
Statistics
Day High
1.35
Day Low
1.35
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
48.18M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
2NovConfirmed
Expected EPS
-1.68
Actual EPS
-0.77
People Also Follow
This list is based on the watchlists of people on Stock Events who follow C5G.F. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Indivior
INDV.LSE
Mkt Cap1.06B
Alkermes
ALKS
Mkt Cap4.2B
Titan Pharmaceuticals (de)
TTNP
Mkt Cap5.81M
Durect
DRRX
Mkt Cap49.35M
Collegium Pharmaceutical
COLL
Mkt Cap1.09B
Supernus Pharmaceuticals
SUPN
Mkt Cap1.66B
Amphastar Pharmaceuticals
AMPH
Mkt Cap1.94B
Acura Pharmaceuticals
ACUR
Mkt Cap1.33M
Pacira BioSciences
PCRX
Mkt Cap901.6M
About
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Show more...
CEO
Mr. Nikolaj Sorensen
Employees
112
Country
SE
ISIN
SE0000736415
WKN
000A0HG6G